This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $81.07 in the latest trading session, marking a +1.99% move from the prior day.
Top Analyst Reports for Microsoft, Mastercard & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).
Atea (AVIR) Plunges on Oral COVID Candidate Study Failure
by Zacks Equity Research
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.
Stock Market News for Oct 20, 2021
by Zacks Equity Research
The S&P 500 and Nasdaq recoded the largest four consecutive winning stretch since July, lifted by an encouraging third-quarter corporate earnings result.
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
by Zacks Equity Research
Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.
J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View
by Zacks Equity Research
J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $78.33, marking a -0.79% move from the previous day.
Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill
by Zacks Equity Research
Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Bristol Myers (BMY) UC Candidate Fails in Phase II Study
by Zacks Equity Research
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $81.94, moving +1.59% from the previous trading session.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in Travel & Tourism ETFs Now?
by Neena Mishra
Travel stocks could benefit from pent-up demand as we return to normal
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates when Tilray (TLRY) reports first-quarter fiscal 2022 results.
RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.
ETFs to Play the Reopening Trade on Merck's Oral Antiviral Pill News
by Sweta Jaiswal, FRM
Let's take a look at ETFs that are well-poised to gain as the reopening of the U.S. economy may pick up further pace following Merck's announcement.
U.S. Aviation Stocks Gain After Update on Merk's COVID-19 Pill
by Maharathi Basu
Delta Air Lines (DAL) management's commentary that its ticket sales are improving bodes well.
Market Bears Take The Bulls By The Horns As Q4 Kicks Off
by Daniel Laboe
We are not out of the correction woods yet as mega-cap tech breaks below Friday's lows
ETFs to Play Dow Jones' Best Start to October Since 2003
by Sanghamitra Saha
The Dow Jones has recorded its best start to October since 2003.